For candidates with MELD less than 15 at enrollment and HCC the HR was 2.17 (versus DDLT), P = 0.19. For candidates with MELD ≥15 at enrollment and HCC, the HR was 1.10 (versus DDLT), P = 0.91. There is considerable uncertainty Romidepsin research buy regarding the benefit of liver transplantation

in adult candidates with low MELD scores. Prior work demonstrated little or no net survival benefit for transplant candidates with low MELD scores (MELD <15) who received DDLT in the U.S.5 This observation resulted in a major change in deceased donor liver allocation policy in the U.S., termed Share15, in a manner that markedly limited the opportunity for receipt of DDLT for adult candidates with low MELD scores. Subsequent analysis employing SRTR data suggested a positive transplant benefit (incorporating pretransplant and posttransplant mortality risk measures) for transplant candidates at somewhat lower MELD scores.6 The majority of liver transplant candidates with MELD scores of 12 or greater would benefit from liver transplantation based on that analysis. Timely receipt of DDLT for such liver transplant candidates with MELD scores of 12-15, however, is unlikely in the setting of allocation policies that preferentially offer DDLT to candidates with the

highest MELD scores in order to minimize waitlist mortality. For example, in the current analysis only 42% of candidates with MELD <15 who did not undergo LDLT received DDLT within 12 months of donor evaluation. An alternative strategy to achieve timely transplantation Cabozantinib ic50 for candidates with lower MELD scores is LDLT. The A2ALL consortium enrolled a large cohort of patients with low MELD scores for whom LDLT was an option, and thus analysis of patients enrolled in this study provided an opportunity to ascertain whether LDLT in patients with low MELD

offers transplant survival benefit. 上海皓元 As detailed above, receipt of LDLT in candidates without HCC whose MELD scores were less than 15 at time of study enrollment was associated with significant survival advantage in comparison to waiting for, or receiving, DDLT. Such benefit could be the result of either diminished waitlist mortality, or improved posttransplant survival. As posttransplant survival was similar in both LDLT and DDLT recipients in the MELD <15 group, the net survival benefit must be attributed largely to reduced waitlist mortality. Although low MELD scores have been associated with relatively low risk of death at 90 days and 1 year,10-12 10.8% of low MELD patients died on the waitlist at a median of 9.8 months following entry into this cohort. This number approximates the percentage difference in estimated 3-year mortality between the LDLT recipients and non-LDLT recipients (Fig. 2). Avoidance of waitlist deaths as a consequence of timely transplant, as reflected by a median wait for LDLT of 3.